Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia [CLL]; ClinicalTrials.gov identifier #NCT02005471) reported superior progression-free survival (PFS) and o...

Descripción completa

Detalles Bibliográficos
Autores principales: Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara F., D’Rozario, James, Owen, Carolyn J., Assouline, Sarit, Lamanna, Nicole, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Mellink, Clemens, Chyla, Brenda, Panchal, Anesh, Lu, Tong, Wu, Jenny Q., Jiang, Yanwen, Lefebure, Marcus, Boyer, Michelle, Kater, Arnon P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412011/
https://www.ncbi.nlm.nih.gov/pubmed/35605176
http://dx.doi.org/10.1182/blood.2021015014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412011/
https://www.ncbi.nlm.nih.gov/pubmed/35605176
http://dx.doi.org/10.1182/blood.2021015014

Ejemplares similares